Stock Ratings / Health Care / KRYS / financials

PCVX (49) IBRX (38) KYMR (50) QGEN (71) ⌘ Pro Terminal →

Krystal Biotech Inc. (KRYS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$324.55 +0.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Krystal Biotech Inc. (KRYS) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (steady margins, 17% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $9.61B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk A-

Each axis scored 0–20

12M PRICE TARGET CONE+6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KRYS)Realized 20D OHLCV Swing Band: ±6.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How KRYS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$188.9M (48.5% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $50.7M

FY24

Rev $290.5M

FY25

Rev $389.1M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$389.1M	52%	41.5%	$204.8M	$188.9M	16.4%
FY 2024	$290.5M	52%	22.6%	$89.2M	$119.2M	8%
FY 2023	$50.7M	52%	-216.2%	$10.9M	-$91.1M	-2.7%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KRYS)

✓Walkthrough of KRYS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KRYS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +13.10%📐 WEDGE COMPRESSION COIL

2026-11-01O $321.4H $324.6L $321.4C $324.6VOL 190.9K

RES: $365.1SUP: $310.7SMA50: $337.0SMA200: $308.7

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KRYS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KRYS Butterfly Map → + Track KRYS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

34.6%/yr Implied 5Y Growth

vs. +33.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KRYS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KRYS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KRYS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KRYS)

Health Care Rank #53 of 188 ⚔️ PCVX vs KRYS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KRYS vs. PCVX, IBRX, KYMR, QGEN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (26 Tracked Issuers)

Across 188 tracked Health Care securities in the Roarable RQD universe, Krystal Biotech Inc. (KRYS) ranks #53 by composite RQD confidence (72/100, grade B) and #117 by equity capitalization ($9.61B). Within this direct 5-issuer industry benchmark cohort, QGEN leads on earnings valuation at 24.4x trailing P/E, while KRYS leads on capital efficiency and profitability with 16.5% ROIC and — gross margin. KRYS currently leads its immediate peer cohort in composite quantitative strength at 72/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KRYS ACTIVE Krystal Biotech Inc.	B	72/100	46.9x	—	16.5%	+0.97%	$9.61B	Benchmark Subject
PCVX Vaxcyte Inc.	D	49/100	—	—	-27.6%	+1.87%	$9.85B	/pcvx-vs-krys →
IBRX ImmunityBio Inc.	D-	38/100	—	96.0%	-27.3%	-0.79%	$9.26B	/ibrx-vs-krys →
KYMR Kymera Therapeutics Inc.	D	50/100	32.7x	—	-21.4%	+0.07%	$10.19B	/kymr-vs-krys →
QGEN Qiagen N.V.	B-	71/100	24.4x	62.2%	8.0%	+0.02%	$10.37B	/qgen-vs-krys →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001711279

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Krystal Biotech Inc. (KRYS) reported GAAP revenue of $389.1M (+33.9% vs. FY2024 revenue of $290.5M , and +667.5% cumulative change since FY2023) , GAAP net income of $204.8M, operating cash flow of $200.9M, and free cash flow of $188.9M (+58.5% YoY). On the balance sheet, KRYS closed FY2025 with $1.33B in total assets against $51.4M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$389.1M	$204.8M	$200.9M	$188.9M	$1.33B	$51.4M
FY2024 (FY)	2024-12-31	$290.5M	$89.2M	$123.4M	$119.2M	$1.06B	$49.3M
FY2023 (FY)	2023-12-31	$50.7M	$10.9M	-$88.8M	-$91.1M	$5.28B	$1.24B

3. KRYS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KRYS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Krystal Biotech Inc. (NASDAQ: KRYS) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $324.55 (+0.97% 1D, market cap $9.61B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 12/20. Across 188 tracked Health Care issuers, KRYS ranks #53 in composite RQD confidence.

How does KRYS compare to PCVX and IBRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), KRYS carries a Roarable B (72/100 RQD), trailing P/E of 46.9x, gross margin of —, and ROIC of 16.5%. By comparison, PCVX (Vaxcyte Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -27.6%, cap $9.85B) and IBRX (ImmunityBio Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -27.3%, cap $9.26B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KRYS?

Per KRYS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001711279), Krystal Biotech Inc. generated $389.1M in revenue (+33.9% YoY), $204.8M in net income, and $188.9M in free cash flow against $1.33B in total assets and $51.4M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KRYS trading relative to its 50-day, 200-day, and 52-week technical levels?

KRYS last traded at $324.55 (+0.97% on volume of 190,894 shares), positioning the stock -3.70% below its 50-day simple moving average ($337.02) and +5.12% above its 200-day simple moving average ($308.74). Across its 52-week range of $184.02 to $382.54, KRYS sits at the 70.8% percentile with a 14-day RSI of 48.2 (NEUTRAL RANGE) and an implied next-earnings move of ±6.5% ($303.45 to $345.65).

KRYS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Krystal Biotech Inc. (KRYS)?

In FY 2025 (10-K), KRYS converted $389.1M of revenue into a 52% gross margin, 41.5% operating margin, and $188.9M in free cash flow (48.5% FCF margin).

Direct Sub-Reports: KRYS RQD Cockpit KRYS 12M Forecast KRYS Earnings & Move KRYS Dividends & DRIP KRYS Insiders & 13F KRYS Whale Options KRYS Profit Sankey KRYS News & Why